Literature DB >> 12322999

Molecular carcinogenesis of squamous cell carcinomas of the skin.

Yoshiaki Kubo1, Kazutoshi Murao, Kazuya Matsumoto, Seiji Arase.   

Abstract

Squamous cell carcinomas (SCCs) of the skin were suggested to develop through a multistep process that involves activation of proto-oncogenes and/or inactivation of tumor suppressor genes in the human skin keratinocytes. Exposure to ultra-violet (UV), especially UV-B, radiation is the most common cause for these genetic abnormalities in cells. We review causation of SCCs and genetic abnormalities in human SCCs with the current work. To elucidate the multistep process, we developed a method for examining the combinatorial function in vivo of plural genes in human keratinocytes. Using high efficiency retroviral transductions, we could express plural genes serially in normal human primary keratinocytes and use these cells to regenerate human skin on SCID mice. A combinatorial transduction of H-RasV12 and cyclin dependent kinase 4 (CDK4) produced human epidermal neoplasia resembling SCC. These findings were consistent with our previous results of mutation analysis in SCCs, one of which had both mutations of H-Ras gene and the INK4a locus. Therefore, it is suggested that a combination of these genetic abnormalities might be crucial to the carcinogenesis at least in a subset of SCCs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12322999

Source DB:  PubMed          Journal:  J Med Invest        ISSN: 1343-1420


  2 in total

Review 1.  [Relevance of cell culture models in cutaneous tumour biology: part II: complex culture systems].

Authors:  J Hatina; T Ruzicka
Journal:  Hautarzt       Date:  2008-02       Impact factor: 0.751

2.  Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration.

Authors:  Vida Farsam; Abhijit Basu; Martina Gatzka; Nicolai Treiber; Lars A Schneider; Medhanie A Mulaw; Tanja Lucas; Stefan Kochanek; Reinhard Dummer; Mitchell P Levesque; Meinhard Wlaschek; Karin Scharffetter-Kochanek
Journal:  Oncotarget       Date:  2016-12-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.